The use of cefotaxime for the treatment of common infections: In vitro, pharmacokinetic and clinical considerations

被引:0
|
作者
Wilson, WR
Bouza, E
Lode, H
Mouton, Y
机构
关键词
cefotaxime; community-acquired infection; nosocomial infection; pediatric patients;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The use of the broad-spectrum cephalosporin, cefotaxime, in internal medicine is well-established, particularly in the treatment of moderately severe to severe community- and hospital-acquired infections. It is particularly useful for infections of the lower respiratory tract, urinary and biliary systems, skin and soft tissue, and in serious conditions, such as meningitis, particularly in pediatric patients. Knowledge of the pharmacokinetic and pharmacodynamic properties of cefotaxime supports the view that low dose (1-2 g), low frequency (12-hourly) dosage regimens are applicable to many mild-to-moderately severe infections, including community-acquired pneumonia, caused by susceptible organisms.
引用
收藏
页码:5 / 18
页数:14
相关论文
共 50 条
  • [21] Use of aminoglycosides in elderly patients - Pharmacokinetic and clinical considerations
    Morike, K
    Schwab, M
    Klotz, U
    DRUGS & AGING, 1997, 10 (04) : 259 - 277
  • [22] PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS ON THE CLINICAL USE OF GLUCOSAMINE IN OSTEOARTHRITIS
    Altman, R. D.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 394 - 394
  • [23] CLINICAL-EXPERIENCE WITH CEFOTAXIME IN THE TREATMENT OF SERIOUS BONE AND JOINT INFECTIONS
    LEFROCK, JL
    CARR, BB
    REVIEWS OF INFECTIOUS DISEASES, 1982, 4 : S465 - S471
  • [24] CEFOTAXIME IN THE TREATMENT OF STAPHYLOCOCCAL INFECTIONS - COMPARISON OF IN-VITRO AND IN-VIVO STUDIES
    ALDRIDGE, KE
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 22 (1-2) : 195 - 201
  • [25] THE USE OF CEFOTAXIME IN SEVERE INFECTIONS OF THE NEONATE
    PESKINE, F
    ASTRUC, J
    RODIERE, M
    ECHENNE, B
    BRUNEL, D
    PATHOLOGIE BIOLOGIE, 1984, 32 (10): : 1040 - 1042
  • [26] Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma
    Kim, Hannah Yejin
    Upadhyay, Parth J.
    Fahmy, Alia
    Liu, Xiaoman
    Duong, Janna K.
    Boddy, Alan V.
    CLINICAL PHARMACOKINETICS, 2019, 58 (08) : 1029 - 1043
  • [27] Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis
    Berends, Sophie E.
    Strik, Anne S.
    Lowenberg, Mark
    D'Haens, Geert R.
    Mathot, Ron A. A.
    CLINICAL PHARMACOKINETICS, 2019, 58 (01) : 15 - 37
  • [28] Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma
    Hannah Yejin Kim
    Parth J. Upadhyay
    Alia Fahmy
    Xiaoman Liu
    Janna K. Duong
    Alan V. Boddy
    Clinical Pharmacokinetics, 2019, 58 : 1029 - 1043
  • [29] Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis
    Sophie E. Berends
    Anne S. Strik
    Mark Löwenberg
    Geert R. D’Haens
    Ron A. A. Mathôt
    Clinical Pharmacokinetics, 2019, 58 : 15 - 37
  • [30] THE ROLE OF CEFOTAXIME IN THE TREATMENT OF SURGICAL INFECTIONS
    WITTMANN, DH
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 22 (1-2) : 173 - 182